Preimplantation Genetic Diagnosis (PGD) Proven Experience
Make sure your next IVF cycle has the best chance for a successful outcome.
Natera is a pioneer in developing tests for preimplantation genetic diagnosis (PGD) performed during in-vitro fertilization. In 2008, we were the first PGD reference laboratory to offer rapid turnaround microarray PGD. Today, our tests are used in over 100 leading in-vitro fertilization clinics to identify genetic diseases and chromosomal abnormalities in embryos prior to implantation.
Our innovative approach to genetic testing leads to exceptional results – initial data from an ongoing clinical investigation demonstrates that the use of our technology doubles the rate of successful implantation.
If you are considering in-vitro fertilization, genetic testing from Natera can help to increase your chances of having a healthy child.
What is Preimplantation Genetic Diagnosis (PGD)?
Preimplantation Genetic Diagnosis (PGD) is a specialized genetic test used during in vitro fertilization (IVF) to evaluate one cell, or cells, from an embryo for chromosome abnormalities and/or diseases due to a single gene mutation. Each embryo from an IVF cycle is tested separatedly. Embryos with normal test results can be selected for transfer to the mother’s uterus. PGD can be performed either on Day 3 after fertilization, when one cell, called a blastomere is biopsied (removed) from each embryo, or, on Day 5 after fertilization where a few cells from the trophectoderm are biopsied from each embryo. In either case, the biopsided cells are sent to the testing laboratory for analysis and the embryos themselves remain at the IVF center to await the testing results. For Day 3 testing results are delivered on the morning of Day 5 before it is time for embryo transfer. Day 5 testing usually requires that the embryos be frozen until test results are returned, after which the embryos are thawed and transferred in a future IVF cycle.
Parental Support™ provides the most accurate and comprehensive PGD on the market.
Natera's proprietary Parental Support™ technology combines the latest innovations in biomedical research and bioinformatic statistics to deliver highly accurate test results. This advanced bioinformatics technology can test tiny quantities of DNA – as small as that from a single cell – to comprehensively analyze genetic tissue. Parental Support uses parent DNA as reference data to compare to the embryo DNA, producing results that are far more reliable than conventional testing methods.
Parental Support is Natera's unique process (available only through Partner IVF Clinics) to interpret the read-out from the scanner with high accuracy and reliability. Natera uses information from parent biological samples to interpret the data from the microarray. Results are reported for all 24 chromosomes with turnaround in time for Day 5 transfer without embryo freezing when Day 3 embryo biopsy is performed.
Parental Support technology is built into all of our products, decreasing the risk of misdiagnosis and delivering the most comprehensive genetic insights possible. With results that are typically >99% accurate, it is a technology both you and your doctor can depend on.